Published in AIDS Behav on May 01, 2015
Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice. Curr Opin HIV AIDS (2016) 1.04
Cascade of Refusal-What Does It Mean for the Future of Treatment as Prevention in Sub-Saharan Africa? Curr HIV/AIDS Rep (2016) 0.86
Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S. AIDS Behav (2016) 0.84
Substance Use and HIV Risk Among Men Who Have Sex With Men in Africa: A Systematic Review. J Acquir Immune Defic Syndr (2017) 0.76
"Since both of us are using antiretrovirals, we have been supportive to each other": facilitators and barriers of pre-exposure prophylaxis use in heterosexual HIV serodiscordant couples in Kisumu, Kenya. J Int AIDS Soc (2016) 0.75
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03
Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med (2008) 7.46
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29
Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med (2010) 5.85
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis (2014) 5.59
The reliability of the Alcohol Timeline Followback when administered by telephone and by computer. Drug Alcohol Depend (1996) 5.35
The expanding epidemics of HIV type 1 among men who have sex with men in low- and middle-income countries: diversity and consistency. Epidemiol Rev (2010) 4.39
Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS (2012) 4.26
HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. Lancet Infect Dis (2014) 3.65
Men who have sex with men and HIV/AIDS in sub-Saharan Africa. Lancet (2009) 3.51
Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med (2013) 2.44
High HIV-1 incidence, correlates of HIV-1 acquisition, and high viral loads following seroconversion among MSM. AIDS (2013) 2.10
Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med (2014) 2.08
Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav (2013) 2.03
The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med (2013) 1.98
Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One (2012) 1.84
Identifying at-risk populations in Kenya and South Africa: HIV incidence in cohorts of men who report sex with men, sex workers, and youth. J Acquir Immune Defic Syndr (2012) 1.84
High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav (2013) 1.75
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet (2006) 31.79
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA (2006) 11.71
Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ (2008) 8.70
Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med (2006) 8.57
Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA (2006) 7.14
Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med (2012) 7.04
Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med (2010) 6.26
Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS (2007) 5.97
Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS (2003) 5.52
Successes and challenges of HIV prevention in men who have sex with men. Lancet (2012) 4.94
Routine HIV testing in Botswana: a population-based study on attitudes, practices, and human rights concerns. PLoS Med (2006) 4.86
Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl (2012) 4.65
Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr (2004) 4.58
Standardization of cytokine flow cytometry assays. BMC Immunol (2005) 4.55
Food insufficiency is associated with high-risk sexual behavior among women in Botswana and Swaziland. PLoS Med (2007) 4.48
Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt) (2008) 4.38
Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med (2009) 4.34
Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS (2012) 4.26
Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr (2010) 4.20
Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials (2004) 3.75
The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr (2009) 3.67
Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. Clin Infect Dis (2002) 3.53
Men who have sex with men and HIV/AIDS in sub-Saharan Africa. Lancet (2009) 3.51
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr (2012) 3.44
Albendazole treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-controlled trial. AIDS (2008) 3.42
Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav (2009) 3.39
Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa. AIDS (2007) 3.26
Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis (2007) 3.16
Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One (2008) 3.13
Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav (2010) 3.08
Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc (2013) 3.00
Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa. J Acquir Immune Defic Syndr (2009) 2.99
Food insecurity is associated with incomplete HIV RNA suppression among homeless and marginally housed HIV-infected individuals in San Francisco. J Gen Intern Med (2008) 2.97
HIV seroprevalence among homeless and marginally housed adults in San Francisco. Am J Public Health (2004) 2.96
Longitudinal antiretroviral adherence in HIV+ Ugandan parents and their children initiating HAART in the MTCT-Plus family treatment model: role of depression in declining adherence over time. AIDS Behav (2009) 2.86
'Are you on the market?': a capture-recapture enumeration of men who sell sex to men in and around Mombasa, Kenya. AIDS (2007) 2.76
The Chinese free antiretroviral treatment program: challenges and responses. AIDS (2007) 2.73
Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS (2010) 2.70
Food insecurity is associated with morbidity and patterns of healthcare utilization among HIV-infected individuals in a resource-poor setting. AIDS (2012) 2.63
A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis (2006) 2.61
Antiretroviral therapy is associated with increased fertility desire, but not pregnancy or live birth, among HIV+ women in an early HIV treatment program in rural Uganda. AIDS Behav (2008) 2.53
Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis (2007) 2.51
Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med (2013) 2.44
Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS (2011) 2.43
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr (2014) 2.43
The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS (2007) 2.39
CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS One (2009) 2.37
Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin Infect Dis (2004) 2.33
Conceptual framework for understanding the bidirectional links between food insecurity and HIV/AIDS. Am J Clin Nutr (2011) 2.32
The association between food insecurity and mortality among HIV-infected individuals on HAART. J Acquir Immune Defic Syndr (2009) 2.31
Doubts about DOT: antiretroviral therapy for resource-poor countries. AIDS (2003) 2.28
Internalized stigma, social distance, and disclosure of HIV seropositivity in rural Uganda. Ann Behav Med (2013) 2.25
Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda. PLoS One (2010) 2.24
Antiretroviral therapy refusal among newly diagnosed HIV-infected adults. AIDS (2011) 2.21
Failure to initiate antiretroviral therapy, loss to follow-up and mortality among HIV-infected patients during the pre-ART period in Uganda. J Acquir Immune Defic Syndr (2013) 2.15
Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr (2013) 2.13
Basic subsistence needs and overall health among human immunodeficiency virus-infected homeless and unstably housed women. Am J Epidemiol (2011) 2.12
Steep declines in population-level AIDS mortality following the introduction of antiretroviral therapy in Addis Ababa, Ethiopia. AIDS (2009) 2.09
Dynamics and constraints of early infant diagnosis of HIV infection in Rural Kenya. AIDS Behav (2012) 2.07
Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses (2010) 2.05
BRIEF REPORT: the aging of the homeless population: fourteen-year trends in San Francisco. J Gen Intern Med (2006) 2.03
Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med (2007) 2.00
Causes of death on antiretroviral therapy: a post-mortem study from South Africa. PLoS One (2012) 1.99
Managing the demand for global health education. PLoS Med (2011) 1.96
Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS (2009) 1.95
A population-based study on alcohol and high-risk sexual behaviors in Botswana. PLoS Med (2006) 1.95
Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis (2009) 1.94
Food insecurity among homeless and marginally housed individuals living with HIV/AIDS in San Francisco. AIDS Behav (2009) 1.91
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine (2008) 1.89
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine (2011) 1.88
Food insecurity, depression and the modifying role of social support among people living with HIV/AIDS in rural Uganda. Soc Sci Med (2012) 1.88
Revolving doors: imprisonment among the homeless and marginally housed population. Am J Public Health (2005) 1.86
Evaluating the InterVA model for determining AIDS mortality from verbal autopsies in the adult population of Addis Ababa. Trop Med Int Health (2010) 1.86
Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med (2006) 1.85
Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One (2012) 1.84
Identifying at-risk populations in Kenya and South Africa: HIV incidence in cohorts of men who report sex with men, sex workers, and youth. J Acquir Immune Defic Syndr (2012) 1.84
HIV counseling and testing practices at an urban hospital in Kampala, Uganda. AIDS Behav (2006) 1.83
Challenges in using mobile phones for collection of antiretroviral therapy adherence data in a resource-limited setting. AIDS Behav (2010) 1.83
Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One (2010) 1.83
Assessing the effectiveness of antiretroviral adherence interventions. Using marginal structural models to replicate the findings of randomized controlled trials. J Acquir Immune Defic Syndr (2006) 1.81